Recursion Pharmaceuticals Stock Is Soaring Today: Here's Why

Recursion Pharmaceuticals Inc (NASDAQ:RXRX) shares moved higher Wednesday after JPMorgan upgraded the stock to Overweight ...
Yahoo Finance

Recursion Pharmaceuticals (RXRX) Is Up 8.0% After TUPELO REC-4881 Trial Data Release - What's Changed

In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Benzinga.com

Why Are Shares Of Recursion Pharmaceuticals Higher Today?

Shares of Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) are trading higher Monday after the pharmaceutical company reported positive data from an ongoing trial. What To Know: Recursion ...
Seeking Alpha

Recursion Pharmaceuticals: Artificial Intelligence, Real Disappointment

Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...

Recursion Pharmaceuticals rises as positive Phase 1b/2 trial results for REC-4881 validate AI-driven drug discovery platform

Recursion Pharmaceuticals Inc. (NASDAQ:RXRX) is one of the most active US stocks to buy according to analysts. On December 8, ...